Royalty Report: Drugs, Disease, Pharmaceuticals – Collection: 7344

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 12

Primary Industries

  • Drugs
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Gastrointestinal
  • Pain
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7344

License Grant
The Licensee entered into an exclusive License Agreement (with a right to subLicense) with the Licensor, a nonprofit medical research facility, for the rights to novel modulators of sphingosine phosphate receptors, including modulators to the S1P1R.
License Property
The technology Licensed covers RPC1063.

RMS:  RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).

RPC1063 for the treatment of UC: IBD is comprised of two chronic, autoimmune, GI inflammatory disorders: UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.

Field of Use
RPC1063, is being developed as an oral therapy for the treatment of Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD).

IPSCIO Record ID: 26261

License Grant
The Licensee received a non-exclusive worldwide license to the Licensed Materials from the licensdor, a nonprofit medical research facility. Royalties will be paid until such time as 1) one or more generic versions of such Non-Patent Product are commercially sold, and 2) the Licensee demonstrates to Licensor that sales of such generic products account for a specific percentage of aggregate unit sales in a calendar quarter. The license covers sphingosine 1-phosphate 1 receptor (S1P1R) modulators in countries where no relevant patent protection exists.
License Property
S1P1R modulation causes selective and reversible retention, or sequestration, of circulating lymphocytes in peripheral lymphoid tissue. This sequestration is achieved by modulating cell migration patterns (known as 'lymphocyte trafficking'), specifically preventing self-targeting, or autoreactive, lymphocyte migration to areas of disease inflammation, which is a major contributor to autoimmune disease. S1P1R modulation may also involve the reduction of lymphocyte migration into the central nervous system (CNS), where certain disease processes take place. This therapeutic approach diminishes the activity of autoreactive lymphocytes that are the underlying cause of autoimmune disease.

IPSCIO Record ID: 210693

License Grant
The Licensor granted the Licensee an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and other IL-23R compounds covered by our patent rights that meet certain requirements for all indications of inflammatory bowel disease,IBD, including CD – Crohns disease and UC – ulcerative colitis.
License Property
The Licensor is a biopharmaceutical company with a proprietary technology platform utilized to discover and develop oral targeted therapy-based peptide drugs including PTG-200 for treatments including the treatment of CD and UC.
Field of Use
The Licensee entered the collaboration agreement for the development, manufacture and commercialization of PTG-200 worldwide.

IPSCIO Record ID: 264191

License Grant
The Company executed a license agreement with the University for a worldwide, exclusive license to manufacture, market, sell and sublicense Extracellular Matrix Hydrogel.
License Property
ExtraCellular Matrix Hydrogel (“ECMH”), targets the treatment of multiple gastrointestinal diseases, including Ulcerative Colitis, Crohn’s Disease, and Rectal Mucositis.
Field of Use
This agreement pertains to the drug industry with a field of use limited to human and animal colonic and small intestine therapeutic indications.

ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.

IPSCIO Record ID: 233469

License Grant
The Licensor of England grants to Licensee of Bermuda the exclusive right and license under the Patent Rights, the Technical Information and Manufacturing Technology to develop, have developed, make, have made, use, sell and have sold Products within the Territory. Notwithstanding the foregoing, Licensor may authorize a Specific Third Party, its Affiliates and successors to manufacture Balsalazide within the Territory solely for sale and use outside the Territory.
License Property
The patents and technology are related to Balsalazide, or to prodrugs, analogs or isomers thereof or improvements of any of the foregoing, obtained in any country within the Territory.

Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.

Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.

Field of Use
The product is used for gastrointestinal disease.

First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years.  Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.

IPSCIO Record ID: 263902

License Grant
The Licensor of Germany grants, in respect of the Licensor Patents, the Licensor IP and the Licensor Product Data the sole and exclusive royalty bearing right and license to use the same and to develop, use and Exploit the Product throughout the Territory and a non-exclusive right and license to manufacture and have manufactured the Product in any part of the world for Exploitation in the Territory only.
License Property
The licensed property is a pellet formulation of mesalamine.  

The name of the product is Salofalk® 500 mg, Granu-Stix®.   Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.

The patents include Pellet formulation for the treatment of the intestinal tract,  and, Pellet-type formulation intended for treating the intestinal tract.

Field of Use
The field of use is for the treatment of acute episodes and the maintenance of remission of ulcerative colitis.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.

IPSCIO Record ID: 26279

License Grant
The Licensor entered into a collaboration Agreement with the Licensee for the exclusive worldwide development and commercialization of Entereg for certain indications. The Licensor is responsible for the development of acute indications, such as postoperative ileus, and the Licensee is responsible for the development of chronic indications, such as opioid bowel dysfunction. In the United States, the Licensee and the Licensor are co-developing Entereg and intend to share profits or losses that result from the sale of the product.
License Property
Entereg is a drug which behaves as a peripherally acting µ-opioid antagonist. With limited ability to cross the blood–brain barrier, many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawal.

Opioid analgesics provide pain relief by stimulating opioid receptors located in the central nervous system. There are, however, opioid receptors throughout the body, including the GI tract. By binding to the receptors in the GI tract, opioid analgesics can slow gut motility and disrupt normal GI function that allows for the passage, absorption and excretion of ingested solid materials. This disruption can cause patients to experience significant discomfort and abdominal pain and may result in their reducing or eliminating their pain medication.
Entereg is a small molecule, mu-opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the GI tract without affecting analgesia. We are developing Entereg for both acute and chronic conditions.

IPSCIO Record ID: 240497

License Grant
Under the terms of the collaboration agreement with Licensee, the Licensor will receive a tiered royalty for the sale of OCREVUS.
License Property
OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies.

Primary Progressive Multiple Sclerosis, MS (PPMS) is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 29002

License Grant
The collaboration agreement for the provision of Inflammatory Bowel Disease patient samples and IBD clinical  data.

IPSCIO Record ID: 26622

License Grant
The Licensor hereby grants to the Company an exclusive, including to the exclusion of REVIMMUNE, perpetual subLicense to the SubLicensed Rights throughout the territory, with the right to grant further subLicenses, to develop, promote, market, sell, make, have made, use, import, offer for sale, and commercialize the SubLicensed Products for the SubLicense Indications in the territory. Revimmune is a patent-pending pharmaceutical treatment in late-stage development for a variety of autoimmune diseases.
License Property
Revimmune uses an ultra-high intensity, short-course of an intravenous formulation of an approved drug (cyclophosphamide), in a new patent-pending method to reboot a patient’s immune system, thereby eliminating the autoimmunity, whereas current therapies including oral cyclophosphamide are used chronically to try to suppress the inflammation of autoimmunity. Based on long-term follow-up showing complete remissions, there is substantial evidence that Revimmune has the potential to cure cases of severe refractory autoimmune diseases such as aplastic anemia and myasthenia gravis. The Company's lead indication for Revimmune is multiple sclerosis (MS).

IPSCIO Record ID: 797

License Grant
The Licensor grants the Licensee exclusive, nontransferable Licenses for: the Applications and the Patents; and the Trademarks, until the Patents expire.

The grant of each License hereunder includes the right to grant subLicenses to Related Companies.

License Property
Applications means PCT/US2009/062895, entitled Medication and Treatment for Disease.

Trademarks mean Feldetrexâ„¢, including US Trademark Application No. 77/601,101 and any identical marks later filed in countries other than the United States of America.

Feldetrexâ„¢ drug is a proprietary combination of generic medications which is believed to reduce the symptomatology of Multiple Sclerosis, Fibromyalgia, and Traumatic Brain Injury.
Multiple Sclerosis is a chronic, progressive illness that affects the nerves in the brain, spinal cord, and other parts of the central nervous system.
Fibromyalgia (FM or FMS) is characterized by chronic widespread pain and allodynia (a heightened and painful response to pressure).[1] Its exact cause is unknown but is believed to involve psychological, genetic, neurobiological and environmental factors.

Field of Use
Trial usage of Feldetrex â„¢ has been used in patients with Multiple Sclerosis.

Licensee shall prominently use the Trademark on Licensed Products.

IPSCIO Record ID: 26724

License Grant
This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.
License Property
BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use
The rights granted relate to neurological symptoms.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.